(64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate
- PMID: 27145400
- DOI: 10.1021/acs.molpharmaceut.6b00143
(64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate
Abstract
A number of folate-based radioconjugates have been synthesized and evaluated for nuclear imaging purposes of folate receptor (FR)-positive tumors and potential therapeutic application. A common shortcoming of radiofolates is, however, a significant accumulation of radioactivity in the kidneys. This situation has been faced by modifying the folate conjugate with an albumin-binding entity to increase the circulation time of the radiofolate, which led to significantly improved tumor-to-kidney ratios. The aim of this study was to develop an albumin-binding folate conjugate with a NODAGA-chelator (rf42) for labeling with (64)Cu and (68)Ga, allowing application for PET imaging. The folate conjugate rf42 was synthesized in 8 steps, with an overall yield of 5%. Radiolabeling with (64)Cu and (68)Ga was carried out at room temperature within 10 min resulting in (64)Cu-rf42 and (68)Ga-rf42 with >95% radiochemical purity. (64)Cu-rf42 and (68)Ga-rf42 were stable (>95% intact) in phosphate-buffered saline over more than 4 half-lives of the corresponding radionuclide. In vitro, the plasma protein-bound fraction of (64)Cu-rf42 and (68)Ga-rf42 was determined to be >96%. Cell experiments proved FR-specific uptake of both radiofolates, as it was reduced to <1% when KB tumor cells were coincubated with excess folic acid. In vivo, high accumulation of (64)Cu-rf42 and (68)Ga-rf42 was found in KB tumors of mice (14.52 ± 0.99% IA/g and 11.92 ± 1.68% IA/g, respectively) at 4 h after injection. The tumor-to-kidney ratios were in the range of 0.43-0.55 over the first 4 h of investigation. At later time points (up to 72 h p.i. of (64)Cu-rf42) the tumor-to-kidney ratio increased to 0.73. High-quality PET/CT images were obtained 2 h after injection of (64)Cu-rf42 and (68)Ga-rf42, respectively, allowing distinct visualization of tumors and kidneys. Comparison of PET/CT images obtained with (64)Cu-rf42 and a (64)Cu-labeled DOTA-folate conjugate (cm10) clearly proved the superiority of NODAGA for stable coordination of (64)Cu. (64)Cu-cm10 showed high liver uptake, most probably as a consequence of released (64)Cu(2+). The data reported in this study clearly proved the promising features of (64)Cu-rf42, particularly in terms of favorable tumor-to-kidney ratios. The relatively long half-life of (64)Cu (T1/2 = 12.7 h) matches well with the enhanced circulation time of the albumin-binding NODAGA-folate, allowing PET imaging at longer time points after injection than is possible when using (68)Ga (T1/2 = 68 min).
Keywords: 64Cu; 68Ga; KB cells; NODAGA; PET; folate; folate receptor.
Similar articles
-
In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.Mol Pharm. 2012 May 7;9(5):1136-45. doi: 10.1021/mp200418f. Epub 2012 Apr 23. Mol Pharm. 2012. PMID: 22497506
-
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.Nucl Med Biol. 2012 May;39(4):560-9. doi: 10.1016/j.nucmedbio.2011.10.011. Epub 2011 Dec 14. Nucl Med Biol. 2012. PMID: 22172391
-
DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.J Nucl Med. 2013 Jan;54(1):124-31. doi: 10.2967/jnumed.112.107235. Epub 2012 Dec 12. J Nucl Med. 2013. PMID: 23236020
-
Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.Q J Nucl Med Mol Imaging. 2015 Sep;59(3):269-86. Epub 2015 Jul 7. Q J Nucl Med Mol Imaging. 2015. PMID: 26149341 Review.
-
[149/152/155/161Tb]-Labeled DOTA-folate conjugated to an albumin-binding entity.2012 Dec 3 [updated 2012 Dec 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Dec 3 [updated 2012 Dec 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23285495 Free Books & Documents. Review.
Cited by
-
Nano-Drug Delivery Systems Based on Natural Products.Int J Nanomedicine. 2024 Jan 18;19:541-569. doi: 10.2147/IJN.S443692. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38260243 Free PMC article. Review.
-
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Front Med (Lausanne). 2022 Jun 6;9:902155. doi: 10.3389/fmed.2022.902155. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35733858 Free PMC article. Review.
-
The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers.Biomedicines. 2021 Oct 28;9(11):1554. doi: 10.3390/biomedicines9111554. Biomedicines. 2021. PMID: 34829783 Free PMC article. Review.
-
Pharmacokinetic Properties of 68Ga-labelled Folic Acid Conjugates: Improvement Using HEHE Tag.Molecules. 2020 Jun 11;25(11):2712. doi: 10.3390/molecules25112712. Molecules. 2020. PMID: 32545327 Free PMC article.
-
Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of 177Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.Mol Pharm. 2024 Aug 5;21(8):4004-4011. doi: 10.1021/acs.molpharmaceut.4c00369. Epub 2024 Jul 7. Mol Pharm. 2024. PMID: 38973113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical